search
Back to results

Effects of Telemonitoring and Telemedicine Service for Hypertensive Care (Smart-HTN)

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
Telemonitoring
Telemonitoring & Telemedicine
control group
Sponsored by
Chang Hee, Lee
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Hypertension focused on measuring telemonitoring, usual care, telemedicine, telehealth, home care, Health Care Quality, Access, Evaluation

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male and female patients who are able to receive outpatient treatment from over 20 to under 70 years of age.- Over SBP 140mmHg without diabetes or renal failure
  2. Patients who are taking more than one kind of any antihypertensive medications

    • Systolic blood pressure (SBP) ≥ 140mmHg in patient with diabetes mellitus and renal disease or
    • Systolic blood pressure (SBP) ≥ 130mmHg in patient without diabetes mellitus and renal disease
  3. Patients who are able to understand the purpose of this trial and to read and write
  4. Patients who are able to use Smart Care PC for this trial
  5. Patients who participate voluntarily and sign the informed consent

Exclusion Criteria:

  1. Patients with severe hypertension (mean of two seated SBP ≥200 mmHg) at screening visit blood pressure measurement.
  2. Patients with secondary hypertension.
  3. HbA1c>11%.
  4. Patients are currently being hospitalized or planning to hospitalize due to hypertension.
  5. Patients with severe renal disease (above 1.5 times the upper limit of normal serum creatinine levels).
  6. Patients with any severe liver disease including cirrhosis (AST or ALT: above 3 times the upper limit of normal).
  7. Patients who have been suffered cardiac infarction or severe coronary artery disease within 6 months, or with clinically significant congestive heart failure or heart valve defects.
  8. Patients with phthisis, autoimmune disease or connective tissue disease.
  9. Patients on medication therapies which may interfere with their blood pressure.
  10. Patients with known history of allergic reaction or contraindication to angiotensin II antagonists.
  11. Pregnant or lactating woman.
  12. Patients with known history of alcoholism, mental illness, or drug dependency.
  13. Patients who have participated in other study within 12 weeks prior to screening visit.
  14. Any clinically significant medical condition including neurologic disease, gastrointestinal disease or malignant tumor, etc., which may affect the test results, or any other medical condition which in the opinion of the investigator makes the patients unsuitable for participation in the trial.

Sites / Locations

  • Keimyung University Dongsan Medical Center
  • Yeungnam University Medical Center
  • Yonsei University Health System

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Other

Arm Label

Telemonitoring group

Telemonitoring & Telemedicine group

Control group

Arm Description

The subjects who are assigned in the Telemonitoring group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring group require site visit once per 2 months (8weeks)

The subjects who are assigned in the Telemonitoring & Telemedicine group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring & Telemedicine group take remote medical treatment through video telephone instead of visiting study site.

The subjects who are assigned in the Control group require site visit once per 2 months (8weeks)

Outcomes

Primary Outcome Measures

Clinic blood pressure
blood pressure value when hospital visiting Clinic blood pressure Changes in mean SBP(Systolic Blood Pressure) from baseline to 24 weeks visit

Secondary Outcome Measures

Clinic blood pressure-Diastolic Blood Pressure(DBP)
Changes in mean Diastolic Blood Pressure(DBP) from baseline to 24 weeks visit
Percentage of subjects who achieved goal clinic blood pressure
Percentage of subjects who achieved blood pressure under 140/90mmHg at 24 weeks visit (under 130/80mmHg in subjects with diabetes mellitus and renal disease)
24 hours ABP(Ambulatory Blood Pressure)
BP measured at baseline and after administration of antihypertensive drugs at 24 weeks Mean values of 24 hours blood pressure (SBP / DBP) will be used for analysis
Percentage of subjects who achieved 24 hours ABP(Ambulatory Blood Pressure) goal
Percentage of subjects who achieved average daytime BP of 24hrs ABPM under 135/85mmHg (under 130/80mmHg in subjects with diabetes mellitus and renal disease) Average daytime BP will be calculated with average of each hourly mean from 07:00 to 22:59 of the Clock time
Self blood pressure measurement
Mean value of each week of self blood pressure measurement (Systolic/Diastolic) from baseline to 24 weeks
Medication compliance
Patients diary will be recorded and medication compliance will be calculated by calculating the number of days administered antihypertensive drugs during the study Drugs compliance = the number of days administered antihypertensive drugs / participated period in this study * 100%
Reduction of body mass index
Changes of Body Mass Index(BMI) - Body Mass Index(BMI)=Body weight (kg)/Height2(m) from baseline to 24 weeks
Assessment of patients' satisfaction
Only remote monitoring group and remote visit + remote monitoring group are applicable

Full Information

First Posted
March 31, 2011
Last Updated
January 29, 2020
Sponsor
Chang Hee, Lee
Collaborators
LG Electronics Inc., Purdue University
search

1. Study Identification

Unique Protocol Identification Number
NCT01335984
Brief Title
Effects of Telemonitoring and Telemedicine Service for Hypertensive Care
Acronym
Smart-HTN
Official Title
A Multi-center, Randomized, Parallel, Interventional, Open Label Trial to Compare the Blood Pressure-lowering Effect of Conventional Treatment and Smart Care Service in Hypertensive Patients Receiving Any Conventional Treatment
Study Type
Interventional

2. Study Status

Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
January 2011 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
August 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Chang Hee, Lee
Collaborators
LG Electronics Inc., Purdue University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a multi-centered, randomized, parallel group, interventional & open label clinical trial accessing efficacy of intervention effect by smart care system over existing treatment group for lowering blood pressure of hypertension patients taking anti-hypertension drug.
Detailed Description
Objectives : To evaluate superiority in blood pressure lowering effect of the Smart Care Service compared to the conventional treatment in hypertensive patients receiving any conventional antihypertensive medication Test and control group Control group : The subject group who is receiving any conventional treatment (hospital visit). Test groups Conventional treatment + remote monitoring group: The subject group who is receiving the health care services using conventional treatment (hospital visit) and remote monitoring. Remote visit + remote monitoring group: The subject group who is receiving remote visit and remote monitoring using videotelephony Target Subject: Hypertensive patients receiving any conventional antihypertensive medication

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
telemonitoring, usual care, telemedicine, telehealth, home care, Health Care Quality, Access, Evaluation

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
440 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Telemonitoring group
Arm Type
Experimental
Arm Description
The subjects who are assigned in the Telemonitoring group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring group require site visit once per 2 months (8weeks)
Arm Title
Telemonitoring & Telemedicine group
Arm Type
Experimental
Arm Description
The subjects who are assigned in the Telemonitoring & Telemedicine group should perform body composition measurement with self blood pressure measurement, and shall transmit the results to the Smart Care Serve via Smart Care PC. Telemonitoring & Telemedicine group take remote medical treatment through video telephone instead of visiting study site.
Arm Title
Control group
Arm Type
Other
Arm Description
The subjects who are assigned in the Control group require site visit once per 2 months (8weeks)
Intervention Type
Procedure
Intervention Name(s)
Telemonitoring
Other Intervention Name(s)
Smartcare System : Telemonitoring
Intervention Description
The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device. The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center.
Intervention Type
Procedure
Intervention Name(s)
Telemonitoring & Telemedicine
Other Intervention Name(s)
Smartcare System : Telemonitoring & Telemedicine
Intervention Description
The subjects who are assigned in the Telemonitoring & Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group. Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions.
Intervention Type
Other
Intervention Name(s)
control group
Other Intervention Name(s)
Self-BP measuring
Intervention Description
- The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring). The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
Primary Outcome Measure Information:
Title
Clinic blood pressure
Description
blood pressure value when hospital visiting Clinic blood pressure Changes in mean SBP(Systolic Blood Pressure) from baseline to 24 weeks visit
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Clinic blood pressure-Diastolic Blood Pressure(DBP)
Description
Changes in mean Diastolic Blood Pressure(DBP) from baseline to 24 weeks visit
Time Frame
24 weeks
Title
Percentage of subjects who achieved goal clinic blood pressure
Description
Percentage of subjects who achieved blood pressure under 140/90mmHg at 24 weeks visit (under 130/80mmHg in subjects with diabetes mellitus and renal disease)
Time Frame
24 weeks
Title
24 hours ABP(Ambulatory Blood Pressure)
Description
BP measured at baseline and after administration of antihypertensive drugs at 24 weeks Mean values of 24 hours blood pressure (SBP / DBP) will be used for analysis
Time Frame
24 weeks
Title
Percentage of subjects who achieved 24 hours ABP(Ambulatory Blood Pressure) goal
Description
Percentage of subjects who achieved average daytime BP of 24hrs ABPM under 135/85mmHg (under 130/80mmHg in subjects with diabetes mellitus and renal disease) Average daytime BP will be calculated with average of each hourly mean from 07:00 to 22:59 of the Clock time
Time Frame
24 weeks
Title
Self blood pressure measurement
Description
Mean value of each week of self blood pressure measurement (Systolic/Diastolic) from baseline to 24 weeks
Time Frame
24 weeks
Title
Medication compliance
Description
Patients diary will be recorded and medication compliance will be calculated by calculating the number of days administered antihypertensive drugs during the study Drugs compliance = the number of days administered antihypertensive drugs / participated period in this study * 100%
Time Frame
24 weeks
Title
Reduction of body mass index
Description
Changes of Body Mass Index(BMI) - Body Mass Index(BMI)=Body weight (kg)/Height2(m) from baseline to 24 weeks
Time Frame
24 weeks
Title
Assessment of patients' satisfaction
Description
Only remote monitoring group and remote visit + remote monitoring group are applicable
Time Frame
24 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female patients who are able to receive outpatient treatment from over 20 to under 70 years of age.- Over SBP 140mmHg without diabetes or renal failure Patients who are taking more than one kind of any antihypertensive medications Systolic blood pressure (SBP) ≥ 140mmHg in patient with diabetes mellitus and renal disease or Systolic blood pressure (SBP) ≥ 130mmHg in patient without diabetes mellitus and renal disease Patients who are able to understand the purpose of this trial and to read and write Patients who are able to use Smart Care PC for this trial Patients who participate voluntarily and sign the informed consent Exclusion Criteria: Patients with severe hypertension (mean of two seated SBP ≥200 mmHg) at screening visit blood pressure measurement. Patients with secondary hypertension. HbA1c>11%. Patients are currently being hospitalized or planning to hospitalize due to hypertension. Patients with severe renal disease (above 1.5 times the upper limit of normal serum creatinine levels). Patients with any severe liver disease including cirrhosis (AST or ALT: above 3 times the upper limit of normal). Patients who have been suffered cardiac infarction or severe coronary artery disease within 6 months, or with clinically significant congestive heart failure or heart valve defects. Patients with phthisis, autoimmune disease or connective tissue disease. Patients on medication therapies which may interfere with their blood pressure. Patients with known history of allergic reaction or contraindication to angiotensin II antagonists. Pregnant or lactating woman. Patients with known history of alcoholism, mental illness, or drug dependency. Patients who have participated in other study within 12 weeks prior to screening visit. Any clinically significant medical condition including neurologic disease, gastrointestinal disease or malignant tumor, etc., which may affect the test results, or any other medical condition which in the opinion of the investigator makes the patients unsuitable for participation in the trial.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sungha Park, M.D.
Organizational Affiliation
Yonsei University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Keimyung University Dongsan Medical Center
City
Daegu
Country
Korea, Republic of
Facility Name
Yeungnam University Medical Center
City
Daegu
Country
Korea, Republic of
Facility Name
Yonsei University Health System
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

Effects of Telemonitoring and Telemedicine Service for Hypertensive Care

We'll reach out to this number within 24 hrs